Magic™ Humanized PD-L1/TIM-3 Dual Immune Checkpoint Knock-In Mice

  • Check with publisher
  • Published date: February 11, 2020
    • Shirley, New York, United States

The programmed cell death-ligand 1 (PD-L1), also known as B7-H1 or CD274, is commonly expressed on the surface of dendritic cells or macrophages. PD-L1 belongs to the family of immune checkpoint proteins and act as a co-inhibitory factor, which can suppress or limit the development of the T cell response. When bound to PD-1 receptors on the activated T cells, PD-L1 expressed on the tumor cells leads to the inhibition of the cytotoxic T cells. https://www.creative-biolabs.com/drug-discovery/therapeutics/magic-humanized-pd-l1-tim-3-dual-immune-checkpoint-knock-in-mice.htm .

Jerry Carter
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Magic™ Humanized PD-L1/TIGIT Dual Immune Checkpoint Knock-In Mice

    Magic™ Humanized PD-L1/TIGIT Dual Immune Checkpoint Knock-In Mice

    Biomedical Sciences Shirley (New York) February 11, 2020 Check with publisher

    Immune checkpoint-targeted therapy is producing unprecedented clinical results in various kind of cancer patients. Currently, researchers continue to identify an increasing number of immune checkpoints as novel targets for anti-tumor therapy. Co-enga...

  • Magic™ Humanized PD-L1/OX40 Dual Immune Checkpoint Knock-In Mice

    Magic™ Humanized PD-L1/OX40 Dual Immune Checkpoint Knock-In Mice

    Biomedical Sciences Shirley (New York) February 11, 2020 Check with publisher

    Therapeutic antibodies designed to block immune checkpoint receptors or activate immune-stimulatory receptors are a potent strategy to treat cancer and function by modulating a patient's own immune system. The combination immunotherapies that associa...

  • Magic™ Humanized PD-L1/LAG-3 Dual Immune Checkpoint Knock-In Mice

    Magic™ Humanized PD-L1/LAG-3 Dual Immune Checkpoint Knock-In Mice

    Biomedical Sciences Shirley (New York) February 11, 2020 Check with publisher

    Immune checkpoint inhibitors that target coinhibitory T cell molecules are becoming a new pillar of cancer therapy by promoting anticancer immune responses. Nevertheless, current immune checkpoint-based therapies are effective only for a portion of c...